15 Years of Fumaderm®: Fumaric acid esters for the systemic treatment of moderate and severe psoriasis vulgaris;15 Jahre Fumaderm®: Fumarsäureester für die systemische Behandlung der mittelschweren und schweren Psoriasis vulgaris

JDDG - Journal of the German Society of Dermatology

Volumn 7, Issue SUPPL. 2, 2009, Pages

  Mrowietz, Ulrich ^a   Rostami Yazdi, Martin ^a   Neureither, Marcus ^b   Reich, Kristian ^c  

^a UNIVERSITY HOSPITAL SCHLESWIG HOLSTEIN   (Germany)

^b Biogen GmbH   (Germany)

^c Dermatologikum Hamburg ^*  (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ADALIMUMAB; ANGIOTENSIN 2 RECEPTOR ANTAGONIST; ANTICOAGULANT AGENT; ANTICONVULSIVE AGENT; ANTIDIABETIC AGENT; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIPOTRIOL; CALCIUM CHANNEL BLOCKING AGENT; CREATININE; CYCLOSPORIN; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; EFALIZUMAB; ETANERCEPT; ETRETIN; FUMADERM; FUMARIC ACID; FUMARIC ACID DIMETHYL ESTER; FUMARIC ACID ETHYL ESTER; INFLIXIMAB; METHOTREXATE; DERMATOLOGICAL AGENT; FUMARIC ACID DERIVATIVE;

ARTHRITIS; CREATININE BLOOD LEVEL; DIABETES MELLITUS; DRUG INDICATION; DRUG TOLERABILITY; DYSLIPIDEMIA; EOSINOPHILIA; GASTROINTESTINAL SYMPTOM; HOT FLUSH; HUMAN; MORBIDITY; MUSCLE HYPERTONIA; PHOTOTHERAPY; PROTEINURIA; PSORIASIS VULGARIS; PUVA; REVIEW; RISK FACTOR; TREATMENT CONTRAINDICATION; ULTRAVIOLET B RADIATION; URINALYSIS; PSORIASIS;

DERMATOLOGIC AGENTS; FUMARATES; HUMANS; PSORIASIS;

EID: 63849201620     PISSN: 16100379     EISSN: 16100387     Source Type: Journal    
DOI: 10.1111/j.1610-0387.2009.07059.x     Document Type: Review

References (45)

1. Henseler T, Christophers E. Disease concomitance in psoriasis. J Am Acad Dermatol 1995; 32: 982-6.
2. Augustin M et al. Verordnung von antipsoriatischen Systemtherapeutika in Deutschland. J Dtsch Dermatol Ges. (im Druck).
3. Nast A, Kopp IB, Augustin M, Banditt KB, Boehncke W-H, Follmann M, Friedrich M, Huber M, Kahl C, Klaus J, Koza J, Kreiselmaier I, Mohr J, Mrowietz U, Ockenfels H-M, Orzechowski H-D, Prinz J, Reich K, Rosenbach T, Rosumeck S, Schlaeger M, Schmid-Ott G, Sebastian M, Streit V, Weberschock T, Rzany B. S3-Leitlinie zur Therapie der Psoriasis vulgaris. J Dtsch Dermatol Ges. 2006, Suppl 2; 4: S51-4.
4. Finlay AY. Current severe psoriasis and the rule of tens. Br J Dermatol 2005; 152: 861-7.
5. Reich K, Mrowietz U. Therapieziele bei der Behandlung der Psoriasis. J Dtsch Dermatol Ges. 2007; 5: 566-75.
6. Rapp SR, Feldman SR, Exum ML, Fleischer AB Jr, Reboussin DM. Psoriasis causes as much disability as other major medical diseases. J Am Acad Dermatol 1999; 41: 401-7.
7. Mrowietz U, Elder JT, Barker J. The Importance of disease associations and concomitant therapy fort he long-term management of psoriasis patients. Arch Dermatol Res 2006; 298: 309-19.
8. Ludwig RJ, Herzog C, Rostock A, Ochsendorf FR, Zollner TM, Thaci D, Kaufmann R, Vogl TJ, Boehncke W-H. Psoriasis: a possible risk factor for development of coronary artery calcification. Br J Dermatol. 2007; 156: 271-6.
9. Gelfand JM, Neimann AL, Shin DB, Wang X, Margolis DJ, Troxel AB. Risk of myocardial infarction in patients with psoriasis. JAMA 2006; 296: 1735-41.
10. Mallbris L, Akre O, Granath F, Yin L, Lindelöf B, Ekbom A, Stahle-Bäckdahl M. Increased risk for cardiovascular mortality in psoriasis inpatients but not in outpatients. Eur J Epidemiol. 2004;19: 225-30.
11. Gelfand JM, Troxel AB, Lewis JD, Kurd SK, Shin DB, Wang X, Margolis DJ, Strom BL. The risk of mortality in patients with psoriasis: results from a population-based study. 2007; 143: 1493-9.
12. Gerdes S, Zahl VA, Knopf H, Weichenthal M, Mrowietz U. Comedication related to comorbidities: a study in 1203 hospitalized patients with severe psoriasis. Br J Dermatol. 2008; 159: 1116-23.
13. Augustin M, Krüger K, Radtke MA, Schwippl I, Reich K. Disease severity, quality of life and health care in plaque-type psoriasis: a multicenter cross-sectional study in Germany. Dermatology. 2008; 216: 366-72.
14. Augustin M, Reich K, Reich C, Purwins S, Jeff Rustenbach S, Schäfer I, Radtke M. Quality of psoriasis care in Germany - results of the national study PsoHealth 2007. J Dtsch Dermatol Ges. 2008; 6: 640-5.
15. Fachinformation Fumaderm®, Stand Juni 2008.
16. Schweckendiek W. Behandlung der Psoriasis. Med. Monatsschr. 1959; 13: 103-4.
17. Nieboer C, de Hoop D, Langendijk PN, van Loenen AC, Gubbels J. Fumaric acid therapy in psoriasis: a double-blind comparison between fumaric acid compound therapy and monotherapy with dimethylfumaric acid ester. Dermatologica 1990; 181: 33-7.
18. Litjens NH, van Strijen E, van Gulpen C, Mattie H, van Dissel JT, Thio HB, Nibbering PH. In vitro pharmacokinetics of anti-psoriatic fumaric acid esters. BMC Pharmacol. 2004; 4: 22.
19. Litjens NH, Burggraaf J, van Strijen E, van Gulpen C, Mattie H, Schoemaker RC, van Dissel JT, Thio HB, Nibbering PH. Pharmacokinetics of oral fumarates in healthy subjects. Br J Clin Pharmacol. 2004; 58: 429-32.
20. Werdenberg D, Joshi R, Wolffram S, Merkle HP, Langguth P. Presystemic metabolism and intestinal absorption of antipsoriatic fumaric acid esters. Biopharm Drug Dispos. 2003; 24: 259-73.
21. Rostami-Yazdi M, Clement B, Schmidt TJ, Schinor D, Mrowietz U. Detection of metabolites of fumaric acid esters in human urine: implications for their mode of action. J Invest Dermatol. 2009; 129(1): 231-4.
22. Mrowietz U, Asadullah K. Dimethylfumarate for psoriasis: more than a dietary curiosity. Trends Mol Med. 2005; 1: 43-8.
23. Yazdi MR, Mrowietz U. Fumaric acid esters. Clin Dermatol. 2008; 26: 522-6.
24. Bacharach-Buhles M, Pawlak FM, Matthes U, Joshi RK, Altmeyer P. Fumaric acid esters (FAEs) suppress CD 15- and ODP 4-positive cells in psoriasis. Acta Derm Venereol Suppl (Stockh). 1994; 186: 79-82.
25. Höxtermann S, Nuchel C, Altmeyer P. Fumaric acid esters suppress peripheral CD4- and CD8-positive lymphocytes in psoriasis. Dermatology 1998; 196: 223-30.
26. Schimrigk S, Brune N, Hellwig K, Lukas C, Bellenberg B, Rieks M, Hoffmann V, Pöhlau D, Przuntek H. Oral fumaric acid esters for the treatment of active multiple sclerosis: an open-label, baseline-controlled pilot study. Eur J Neurol. 2006; 13: 604-10.
27. Treumer F, Zhu K, Gläser R, Mrowietz U. Dimethylfumarate is a potent inducer of apoptosis in human T cells. J Invest Dermatol. 2003; 121: 1383-8.
28. Litjens NH, Nibbering PH, Barrois AJ, Zomerdijk TP, Van Den Oudenrijn AC, Noz KC, Rademaker M, Van De Meide PH, Van Dissel JT, Thio B. Beneficial effects of fumarate therapy in psoriasis vulgaris patients coincide with downregulation of type 1 cytokines. Br J Dermatol. 2003; 148: 444-51.
29. Schmidt TJ, Ak M, Mrowietz U. Reactivity of dimethyl fumarate and methyl-hydrogen fumarate towards glutathione and N-acetyl-1-cysteine-Preparation of S-substituted thiosuccinic acid esters. Bioorg Med Chem. 2007; 15: 333-42.
30. Nelson KC, Carlson JL, Newman ML, Sternberg P Jr, Jones DP, Kavanagh TJ, Diaz D, Cai J, Wu M. Effect of dietary inducer dimethylfumarate on glutathione in cultured human retinal pigment epithelial cells. Invest Ophthalmol Vis Sci. 1999; 40: 1927-35.
31. Lehmann JC, Listopad JJ, Rentzsch CU, Igney FH, von Bonin A, Hennekes HH, Asadullah K, Docke WD. Dimethylfumarate induces immunosuppression via glutathione depletion and subsequent induction of heme oxygenase 1. J Invest Dermatol. 2007; 127: 835-45.
32. Loewe R, Holnthoner W, Gröger M, Pillinger M, Gruber F, Mechtcheriakova D, Hofer E, Wolff K, Petzelbauer P. Dimethylfumarate inhibits TNF-induced nuclear entry of NF-kappa B/p65 in human endothelial cells. J Immunol. 2002; 168: 4781-7.
33. Gerdes S, Shakery K, Mrowietz U. Dimethylfumarate inhibits nuclear binding of nuclear factor kappaB but not of nuclear factor of activated T cells and CCAAT/enhancer binding protein beta in activated human T cells. Br J Dermatol. 2007; 156: 838-42.
34. Aronica MA, Mora AL, Mitchell DB, Finn PW Johnson JE, Sheller JR, Boothby MR. Preferential role for NF-kappa B/Rel signaling in the type 1 but not type 2 T cell-dependent immune response in vivo. J Immunol. 1999; 163: 5116-24.
35. Rubant SA, Ludwig RJ, Diehl S, Hardt K, Kaufmann R, Pfeilschifter JM, Boehncke WH. Dimethylfumarate reduces leukocyte rolling in vivo through modulation of adhesion molecule expression. J Invest Dermatol. 2008; 128: 326-31.
36. Exner R, Wessner B, Manhart N, Roth E. Therapeutic potential of glutathione. Wien Klin Wochenschr. 2000; 112: 610-6.
37. Altmeyer PJ, Mathhes U, Pawlak F, Hoffmann K, Frosch P, Ruppert P, Sawko WW, Horn T, Kreysel HW Lutz G, Barth J, Rietzschel I, Rajendra K, Joshi K. Antipsoriatic effect of fumaric acid derivatives. Results of a multicentre double-blind study in 100 patients. J Am Acad Dermatol. 1994; 30: 977-81.
38. Mrowietz U, Christophers E, Altmeyer P. Treatment of psoriasis with fumaric acid esters: results of a prospective multicentre study. Br J Dermatol. 1998; 138: 456-60.
39. Gollnick H, Altmeyer P, Kaufmann R, Ring J, Christophers E, Pavel S, Ziegler J. Topical calcipotriol plus oral fumaric acid is more effective and faster acting than oral fumaric acid monotherapy in the treatment of severe chronic plaque psoriasis vulgaris. Dermatology 2002; 205: 46-53.
40. Reich R, Thaci D, Mrowietz U, Kamps A, Neureither M, Luger T. Langzeiteffekt und -sicherheit von Fumarsäureestern in der Behandlung der Psoriasis. Eine retrospektive Datenerhebung(FUTURE) 2009 eingereicht.
41. Weisenseel P, Kuznetsov AV, Prinz JC. Implementation of the S3-guidelines for systemic and UV therapy of moderate to severe psoriasis vulgaris by an algorithm. J Dtsch Dermatol Ges. 2007; 5: 683-8.
42. Hoefnagel JJ, Thio HB, Willemze R, Bouwes Bavinck JN. Long-term safety aspects of systemic therapy with fumaric acid esters in severe psoriasis. Br J Dermatol. 2003; 149: 363-9.
43. Balasubramaniam P, Stevenson O, Barth-Jones J. Fumaric acid esters in severe psoriais, including experience of use in combination with other systemic modalities. Br J Dermatol. 2004; 150: 741-6.
44. Zhu K, Mrowietz U. Enhancement of antibacterial superoxide-anion generation in human monocytes by fumaric acid esters. Arch Dermatol Res. 2005; 297: 170-6.
45. Mrowietz U, Altmeyer P, Bieber T, Röcken M, Schopf RE, Sterry W. Therapie der Psoriasis mit Fumarsäureestern (Fumaderm®). J. Dtsch Dermatol Ges. 2007; 8: 716-7.